For the quarter ending 2025-09-30, CADL had -$13,724K decrease in cash & cash equivalents over the period. -$10,380K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,269 | 2,583 |
| Depreciation expense | 195 | 487 |
| Impairment of fixed assets | 1 | 82 |
| Loss on the sale and disposal of fixed assets | -328 | -11 |
| Non-cash stock compensation expense | 1,163 | 1,364 |
| Non-cash lease expense | 81 | 151 |
| Non-cash interest expense | 34 | 69 |
| Change in fair value of warrant liability | -1,146 | -20,572 |
| Accretion of debt discount | 21 | 76 |
| Prepaid expenses and other current assets | -61 | 1,771 |
| Other assets | 40 | -18 |
| Accounts payable | -744 | 1,513 |
| Accrued expenses | 1,208 | -1,243 |
| Lease liability | -129 | -275 |
| Net cash used in operating activities | -10,236 | -17,507 |
| Purchase of fixed assets | 144 | 34 |
| Proceeds from the sale of fixed assets | 27 | - |
| Net cash used in investing activities | -117 | -34 |
| Proceeds from issuance of common stock in registered direct offering | -713 | 15,044 |
| Proceeds from sale of common stock, net of issuance costs | 0 | 5,038 |
| Proceeds from option exercises | 20 | 492 |
| Principal payments on term loan | -2,500 | -5,000 |
| Payment of deferred debt issuance costs | 178 | - |
| Net cash provided by financing activities | -3,371 | 15,574 |
| Net decrease in cash, cash equivalents and restricted cash | -13,724 | -1,967 |
| Cash and cash equivalents at beginning of period | 102,920 | - |
| Cash and cash equivalents at end of period | 87,229 | - |
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)